GLPBio

JZL 195

Catalog No.: GC12693Purity:>98.00%
JZL 195 is a highly selective and irreversible dual inhibitor of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), with IC50 values of 2nM and 4nM, respectively.

Products are for research use only. Not for human use. We do not sell to patients.


JZL 195
Cas No.: 1210004-12-8
10mM (in 1mL DMSO)In Stock
$33.00
1
5mgIn Stock
$35.00
1
10mgIn Stock
$57.00
1
25mgIn Stock
$119.00
1
50mgIn Stock
$196.00
1
100mgIn Stock
$314.00
1

Citations

No citations are currently available for this product. Below are selected publications citing GlpBio products.
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

Description

JZL 195 is a highly selective and irreversible dual inhibitor of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), with IC50 values of 2nM and 4nM, respectively[1]. In vivo, JZL 195 elevates the levels of endogenous cannabinoids anandamide (AEA) and 2-arachidonoylglycerol (2-AG)[2]. JZL 195 is commonly used to alleviate neuropathic and inflammatory pain, manage chemotherapy-induced peripheral neuropathy, and investigate potential antihypertensive effects, among other applications[3,4].

In vitro, pretreatment of immortalized human renal proximal tubular HK-2 cells with 250nM JZL 195 for 24h indirectly activated CB1R and significantly increased the mRNA and protein expression levels of erythropoietin (EPO)[5].

In vivo, oral administration of JZL 195 (20mg/kg) for 15 days in a streptozotocin-induced sporadic Alzheimer's disease mouse model significantly reversed the elevated levels of Aβ1-42 in hippocampal tissue[6]. Intraperitoneal injection of JZL 195 (3mg/kg) 2h after nitroglycerin (NTG) administration in Sprague-Dawley rats, with tissue sampling following behavioral tests, significantly reduced the NTG-induced increase in calcitonin gene-related peptide (CGRP) levels[7]. Intraperitoneal administration of JZL 195 (10mg/kg) 45min before bilateral carotid artery occlusion surgery in C3H mice significantly ameliorated ischemia-induced neurological deficits[8].

References:
[1] LONG J Z, NOMURA D K, VANN R E, et al. Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo[J]. Proceedings of the National Academy of Sciences, 2009, 106(48): 20270-20275.
[2] MANDUCA A, MORENA M, CAMPOLONGO P, et al. Distinct roles of the endocannabinoids anandamide and 2-arachidonoylglycerol in social behavior and emotionality at different developmental ages in rats[J]. European Neuropsychopharmacology, 2015, 25(8): 1362-1374.
[3] ANDERSON W B, GOULD M J, TORRES R D, et al. Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine inflammatory pain model[J]. Neuropharmacology, 2014, 81: 224-230.
[4] TOCZEK M, RYSZKIEWICZ P, REMISZEWSKI P, et al. Weak hypotensive effect of chronic administration of the dual FAAH/MAGL inhibitor JZL195 in spontaneously hypertensive rats as revealed by area under the curve analysis[J]. International Journal of Molecular Sciences, 2023, 24(13): 10942.
[5] BARAGHITHY S, SOAE Y, ASSAF D, et al. Renal proximal tubule cell cannabinoid-1 receptor regulates bone remodeling and mass via a kidney-to-bone axis[J]. Cells, 2021, 10(2): 414.
[6] BAJAJ S, ZAMEER S, JAIN S, et al. Effect of the MAGL/FAAH dual inhibitor JZL-195 on streptozotocin-induced Alzheimer’s disease-like sporadic dementia in mice with an emphasis on Aβ, HSP-70, neuroinflammation, and oxidative stress[J]. ACS Chemical Neuroscience, 2022, 13(7): 920-932.
[7] GRECO R, DEMARTINI C, FRANCAVILLA M, et al. Dual inhibition of FAAH and MAGL counteracts migraine-like pain and behavior in an animal model of migraine[J]. Cells, 2021, 10(10): 2543.
[8] MITROSHINA E V, ABOGESSIMENGANE B Z, URAZOV M D, et al. The influence of Glial cell line-derived neurotrophic factor and modulated activity of endocannabinoid system on с3h mice sustainability to ischemic brain injury in vivo[J]. Opera Medica et Physiologica, 2016(S1): 83-84.

Protocol

Cell experiment [1]:

Cell lines

HK-2 cells (Human immortalized renal proximal tubular cells)

Preparation Method

HK-2 cells were treated with 250nM JZL 195 for 24h, after which EPO mRNA and protein expression levels were analyzed by real-time PCR and Western blotting, respectively.

Reaction Conditions

250nM; 24h

Applications

Treatment of JZL 195 can significantly enhance the mRNA and protein expression levels of EPO.
Animal experiment [2]:

Animal models

Sprague-Dawley rat

Preparation Method

Male Sprague-Dawley rats were intraperitoneally injected with 3mg/kg JZL 195 2h after NTG administration. Following behavioral testing, blood samples were collected via decapitation, and serum levels of CGRP were quantified using ELISA.

Dosage form

3mg/kg; i.p.

Applications

Treatment of JZL 195 significantly reduced the increase in CGRP levels caused by NTG.

References:
[1] BARAGHITHY S, SOAE Y, ASSAF D, et al. Renal proximal tubule cell cannabinoid-1 receptor regulates bone remodeling and mass via a kidney-to-bone axis[J]. Cells, 2021, 10(2): 414.
[2] GRECO R, DEMARTINI C, FRANCAVILLA M, et al. Dual inhibition of FAAH and MAGL counteracts migraine-like pain and behavior in an animal model of migraine[J]. Cells, 2021, 10(10): 2543.

Product Documents

Purity:>98.00%Appearance:A solid

Chemical Properties

CAS No.
1210004-12-8
Chemical Name
4-nitrophenyl 4-(3-phenoxybenzyl)piperazine-1-carboxylate
SMILES
O=C(N1CCN(CC2=CC=CC(OC3=CC=CC=C3)=C2)CC1)OC(C=C4)=CC=C4[N+]([O-])=O
Molecular Formula
C24H23N3O5
Molecular Weight
433.46
Solubility
DMF: 5 mg/ml,DMSO: 1.25 mg/ml
Storage
Store at -20°C
General tips
Select a suitable solvent according to the product solubility data. Once prepared, aliquot the stock solution to avoid repeated freeze-thaw cycles.
Use stock solutions within 6 months when stored at -80°C or within 1 month when stored at -20°C.
To improve solubility, warm the tube to 37°C and sonicate it for an appropriate period.
Shipping Condition
Evaluation samples are shipped with blue ice. Other available sizes are shipped at room temperature or with blue ice upon request.

CalculatorsMolarity / Dilution / Molecular Weight / Unit Conversion / In Vivo Formulation / Solubility

g/mol

Reviews

Review for JZL 195

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%